| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
CC4 Cost-Benefit Analysis of Recombinant Erythropoietin in Premature Neonates
|
Wandstrat, TL
|
|
1998
|
1 |
1 |
p. 43-
1 p.
|
artikel
|
| 2 |
CC2 Cost of Preventable Adverse Drug Events in Emergency Department Patients
|
Dominguez-Gil, A
|
|
1998
|
1 |
1 |
p. 42-43
2 p.
|
artikel
|
| 3 |
CC6 Development of Asthma-Specific Outcomes Measures for Children
|
Sweeny, SF
|
|
1998
|
1 |
1 |
p. 44-
1 p.
|
artikel
|
| 4 |
CC5 Incremental Cost-Effectiveness Analysis Comparing 4-Layer Bandage System with And without Apligraf™ for the Outpatient Treatment of Venous Leg Ulcers
|
Attard, C
|
|
1998
|
1 |
1 |
p. 43-44
2 p.
|
artikel
|
| 5 |
CC3 Modeling Side Effect Costs from Literature-Based Data: Steroid-Induced Side Effects in Renal Transplantation
|
Veenstra, DL
|
|
1998
|
1 |
1 |
p. 43-
1 p.
|
artikel
|
| 6 |
CC1 Socioeconomic Efficiency of Prophylaxis of Exacerbations with N-Acetylcysteine in Patients with Chronic Bronchitis
|
Rappenhöner, B
|
|
1998
|
1 |
1 |
p. 42-
1 p.
|
artikel
|
| 7 |
CM2 Clinical Intervention Assessment: Implementation of Default Values for Expediting the Calculation of Cost Savings And Cost Avoidances
|
Mutnick, A
|
|
1998
|
1 |
1 |
p. 91-
1 p.
|
artikel
|
| 8 |
CM5 Discounting Health Benefits in Pharmacoeconomic Analyses: Is It Justified?
|
Caro, JJ
|
|
1998
|
1 |
1 |
p. 92-
1 p.
|
artikel
|
| 9 |
CM1 Estimating the Costs And Outcomes for Different Disease Management Strategies: A Case Study of Cyomegalovirus Infection And Disease
|
Mauskopf, J
|
|
1998
|
1 |
1 |
p. 91-
1 p.
|
artikel
|
| 10 |
CM3 Multivariable Methods for Measuring Treatment Costs in Randomized Trials
|
Polsky, D
|
|
1998
|
1 |
1 |
p. 91-92
2 p.
|
artikel
|
| 11 |
CM6 The Use of Patient Self-Reports to Collect Health Care Resource Utilization Data
|
Crawford, B
|
|
1998
|
1 |
1 |
p. 92-
1 p.
|
artikel
|
| 12 |
CM4 Use of UB-92S And Medicare Cost Reports in A Large, Multi-Center Randomized Trial: The Pursuit Experience
|
Davidson-Ray, L
|
|
1998
|
1 |
1 |
p. 92-
1 p.
|
artikel
|
| 13 |
CVA3 Adherence to Hypertension Therapy: The Effect of Initial Drug Choice
|
Caro, JJ
|
|
1998
|
1 |
1 |
p. 28-
1 p.
|
artikel
|
| 14 |
CVA6 Confounding by Indication in Calcium Channel Blocker Treatment of Hypertension or Angina
|
Mallick, R
|
|
1998
|
1 |
1 |
p. 29-30
2 p.
|
artikel
|
| 15 |
CVA2 Cost-Effectiveness and Economic Efficiency: The Case of Statin Therapy in Secondary Prevention of Cornary Heart Disease
|
Russell, MW
|
|
1998
|
1 |
1 |
p. 28-
1 p.
|
artikel
|
| 16 |
CVA1 Economic Outcomes of Carotid Endrterectomy for Stroke
|
Patterson, HK
|
|
1998
|
1 |
1 |
p. 27-28
2 p.
|
artikel
|
| 17 |
CVA5 Effect of Compliance on Health And Economic Outcomes: Role of Conjugated Estrogen on Depression And Cardiovascular Disorders
|
Heaton, AH
|
|
1998
|
1 |
1 |
p. 29-
1 p.
|
artikel
|
| 18 |
CVB1 Cost of Italian Hypertensive Patient: A Feasibility Study from the Pandora Project
|
Berto, P
|
|
1998
|
1 |
1 |
p. 32-
1 p.
|
artikel
|
| 19 |
CVB2 Development And Cross-Validation of A Comorbidity Index for A Stroke Population
|
Ricci, JF
|
|
1998
|
1 |
1 |
p. 33-
1 p.
|
artikel
|
| 20 |
CVB3 Evaluation of the Costs of Coronary Heart Disease in Belgium
|
Annemans, L
|
|
1998
|
1 |
1 |
p. 33-
1 p.
|
artikel
|
| 21 |
CVB4 In-Hospital Survival of Congestive Heart Failure Patients Treated with Dobutamine or Milrinone
|
Weycker, DA
|
|
1998
|
1 |
1 |
p. 33-34
2 p.
|
artikel
|
| 22 |
CVB5 Preventing Cardiovascular Disease: Is Primary Prevention with Pravastatin Worth the Money?
|
Caro, JJ
|
|
1998
|
1 |
1 |
p. 34-
1 p.
|
artikel
|
| 23 |
CVB6 Torsemide And Furosemide in the Treatment of the EDEMA of Heart Failure: Interim Results of A Randomized Effectiveness Trial
|
Murray, M
|
|
1998
|
1 |
1 |
p. 34-
1 p.
|
artikel
|
| 24 |
DA4 Construction of A Validated, Normalized, Granular Administrative Database And Its Use in Clinical Outcomes Improvement, Clinical Research, And Pharmacoeconomic Research
|
Morris, S
|
|
1998
|
1 |
1 |
p. 88-
1 p.
|
artikel
|
| 25 |
DA5 Disease State Management Tracker: Implementing, Tracking, And Evaluating Clinical Pathways And Outcomes
|
Ambegaonkar, AJ
|
|
1998
|
1 |
1 |
p. 88-89
2 p.
|
artikel
|
| 26 |
DA8 Evaluating Health Outcomes And Pharmacoeconomic Literature
|
Fulda, TR
|
|
1998
|
1 |
1 |
p. 89-90
2 p.
|
artikel
|
| 27 |
DA7 Prospective, Naturalistic Outcomes Measurement: The Schizophrenia Care And Assessment Program (SCAP)
|
Haley, JC
|
|
1998
|
1 |
1 |
p. 89-
1 p.
|
artikel
|
| 28 |
DA6 Strategies for Formulary Comparisons in the Medicaid Managed Care Era
|
Wurtzbacher, JD
|
|
1998
|
1 |
1 |
p. 89-
1 p.
|
artikel
|
| 29 |
DA2 The Role of Patient Registries in Disease Management and Outcomes Research
|
Hartz, SC
|
|
1998
|
1 |
1 |
p. 87-
1 p.
|
artikel
|
| 30 |
DA3 Using Community Pharmacies to Conduct Outcomes Research
|
Ungar, WJ
|
|
1998
|
1 |
1 |
p. 87-88
2 p.
|
artikel
|
| 31 |
DA1 Using Medication History to Measure Indication Bias
|
Leader, S
|
|
1998
|
1 |
1 |
p. 87-
1 p.
|
artikel
|
| 32 |
DM2 Dissemination of Pharmacoeconomic Results to Managed Care Organizations
|
Shreve, JL
|
|
1998
|
1 |
1 |
p. 90-
1 p.
|
artikel
|
| 33 |
DM1 Interpreting And Using Costeffectiveness Results
|
Bala, MV
|
|
1998
|
1 |
1 |
p. 90-
1 p.
|
artikel
|
| 34 |
DM3 Outcomes Research in Medication Use: HCFA'S Health Care Quality Improvement Program
|
Westrick, E
|
|
1998
|
1 |
1 |
p. 90-
1 p.
|
artikel
|
| 35 |
Editorial
|
Smeeding, Jim
|
|
1998
|
1 |
1 |
p. 1-
1 p.
|
artikel
|
| 36 |
GIR3 Cost-Effectiveness of Proton Pump Inhibitors in Gastric ULCER
|
Ikeda, S
|
|
1998
|
1 |
1 |
p. 36-
1 p.
|
artikel
|
| 37 |
GIR1 Economic And Clinical Outcomes Models for the Evaluation of Drug Therapy Strategies in Treatment of Gerd
|
McGhan, WF
|
|
1998
|
1 |
1 |
p. 35-
1 p.
|
artikel
|
| 38 |
GIR2 Noncompliance with Dosing Instructions And Gastrointestinal Outcomes Associated with Alendronate for Osteoporosis in A Large HMO
|
Ettinger, B
|
|
1998
|
1 |
1 |
p. 35-
1 p.
|
artikel
|
| 39 |
GIR6 Predictors of Diagnostic-Related Group Day Outliers in the Medicare End-Stage Renal Disease Population
|
Vilas-Boas, I
|
|
1998
|
1 |
1 |
p. 37-
1 p.
|
artikel
|
| 40 |
GIR4 Prospective Economic Evaluation in A Phase IIIB Renal Transplant Clinical Trial
|
Arnold, RJG
|
|
1998
|
1 |
1 |
p. 36-
1 p.
|
artikel
|
| 41 |
ID6 Cost-Effectiveness of Liposomal Daunorubicin Versus Liposomal Doxorubicin in Kaposi Sarcoma
|
Egan, T
|
|
1998
|
1 |
1 |
p. 39-
1 p.
|
artikel
|
| 42 |
ID4 Evaluation of the Cost-Effectiveness of Management Strategies in Cytomegalovirus Infection And Disease
|
Annemans, L
|
|
1998
|
1 |
1 |
p. 38-39
2 p.
|
artikel
|
| 43 |
ID3 Prescribing Patterns for Treatment of Upper Respiratory Infections
|
McLaughlin, TP
|
|
1998
|
1 |
1 |
p. 38-
1 p.
|
artikel
|
| 44 |
ID1 Randomised Prospective Study Comparing Cost-Effectiveness of Teicoplanin and Vancomycin As Second-Line Empiric Therapy for Infection in Neutropenic Patients
|
Dominguez-Gil, A
|
|
1998
|
1 |
1 |
p. 37-
1 p.
|
artikel
|
| 45 |
ID5 Socio-Economic Relevance of Inpatient Treatment of Skin And Soft Tissue Infections with Tazobactam/Piperacillin 0.5 g/2.0 g in Comparison with Amoxicillin/Clavlanic Acid, Ceftriaxone, And Cefotaxime
|
Bruchhausen, Y
|
|
1998
|
1 |
1 |
p. 39-
1 p.
|
artikel
|
| 46 |
ID2 Willingness to Pay for HIV Prevention: A Study of High-And Low-Risk Groups
|
Flanders, S
|
|
1998
|
1 |
1 |
p. 38-
1 p.
|
artikel
|
| 47 |
MGA3 A New Paradigm for Assessing Health-Related Quality of Life: A Social-Clinical Model
|
Wan, GJ
|
|
1998
|
1 |
1 |
p. 40-41
2 p.
|
artikel
|
| 48 |
MGA4 A Retrospective Approach to Evaluate Qaly: Estimation of Health Utility Index from the SF-36 in A Managed Care Population
|
Sengupta, N
|
|
1998
|
1 |
1 |
p. 41-
1 p.
|
artikel
|
| 49 |
MGA2 Disease Management in Hypertension: The Benefits of Meeting Guideline Goals for Blood Pressure
|
Huse, DM
|
|
1998
|
1 |
1 |
p. 40-
1 p.
|
artikel
|
| 50 |
MGA5 Health Utilities Index: Further Evidence of Responsiveness
|
Torrance, GW
|
|
1998
|
1 |
1 |
p. 41-
1 p.
|
artikel
|
| 51 |
MGA1 Improving Clinical Outcomes by Integrating A Normalized, Standardized, Comparative Database into the Process of Clinical Quality Improvement
|
Bryant, D
|
|
1998
|
1 |
1 |
p. 40-
1 p.
|
artikel
|
| 52 |
MGA6 Survey Strategies in the Revision of the Guidelines for Economic Evaluation: Canada
|
Glennie, JL
|
|
1998
|
1 |
1 |
p. 41-42
2 p.
|
artikel
|
| 53 |
MGB5 Adherence of Health Care Workers to Hepatitis B Vaccination (HBV) Policy is Influenced by Leadership
|
Sutton, EL
|
|
1998
|
1 |
1 |
p. 46-
1 p.
|
artikel
|
| 54 |
MGB6 Formulary Impact Decision Modeling in HMG-COA Reductase Inhibitors
|
Corey, R
|
|
1998
|
1 |
1 |
p. 46-
1 p.
|
artikel
|
| 55 |
MGB1 Poor Adherence to Hypertension Treatment Guidelines: An Analysis of Therapeutic Choices
|
Huse, DM
|
|
1998
|
1 |
1 |
p. 44-45
2 p.
|
artikel
|
| 56 |
MGB3 Postmarketing Outcomes Studies: Benefits And Risks
|
Garfield, FB
|
|
1998
|
1 |
1 |
p. 45-
1 p.
|
artikel
|
| 57 |
MGB4 Relationship Between Quality of Life, Disease Severity, And Physician Visits in Managed Care Patients with Atopic Dermatitis
|
Fagan, S
|
|
1998
|
1 |
1 |
p. 45-46
2 p.
|
artikel
|
| 58 |
MGB2 The Utilization And Costs of Prescription Drugs in A Texas Medicaid Managed Care Pilot Program
|
Johnsrud, MT
|
|
1998
|
1 |
1 |
p. 45-
1 p.
|
artikel
|
| 59 |
MHA3 Comparison of Sumatriptan (IMITREX®) and Over-the-Counter (OTC) Medication Use According to Migraine Severity
|
Yuran, TE
|
|
1998
|
1 |
1 |
p. 26-
1 p.
|
artikel
|
| 60 |
MHA2 Cost Impact of Using Olanzapine at A Veterans Affairs Medical Center
|
Weiss, MA
|
|
1998
|
1 |
1 |
p. 25-
1 p.
|
artikel
|
| 61 |
MHA6 Evaluation of Antidepressant Utilization Patterns and Associated Depression Diagnoses among Patients in A National Managed Care Organization
|
Way, K
|
|
1998
|
1 |
1 |
p. 27-
1 p.
|
artikel
|
| 62 |
MHA5 SSRI Antidepressant Use in Primary Care in the United Kingdom: A Multivariate Analysis
|
Hylan, TR
|
|
1998
|
1 |
1 |
p. 26-27
2 p.
|
artikel
|
| 63 |
MHA4 SSRI Antidepressant Use Patterns and their Relation to Clinical Global Impressions Scores: A Naturalistic Study
|
Hylan, TR
|
|
1998
|
1 |
1 |
p. 26-
1 p.
|
artikel
|
| 64 |
MHA1 The Economic Burden of Alzheimer's Disease to Medicaid in California (MEDI-CAL)
|
Menzin, J
|
|
1998
|
1 |
1 |
p. 25-
1 p.
|
artikel
|
| 65 |
MHB5 Changes in Sexual Function And Bother in Men Treated for Prostate Cancer: Results from the Capsure™ Database
|
Flanders, S
|
|
1998
|
1 |
1 |
p. 31-32
2 p.
|
artikel
|
| 66 |
MHB4 Comparison of Standard Gamble, Time Trade-Off, And Visual Analog Scale Scores for Hypothetical Stroke Health States Using A Computer-Based Program
|
Namjoshi, MA
|
|
1998
|
1 |
1 |
p. 31-
1 p.
|
artikel
|
| 67 |
MHB3 Cost-Effectiveness Evaluation of New Antipsychotics
|
Launois, R
|
|
1998
|
1 |
1 |
p. 30-31
2 p.
|
artikel
|
| 68 |
MHB6 Medical And Economic Relevance of Screening of Stroke Risk by Employees
|
Hansen, N
|
|
1998
|
1 |
1 |
p. 32-
1 p.
|
artikel
|
| 69 |
MHB2 Medical Costs of Venlafaxine Versus Tricyclic or Tetracyclic Antidepressant Therapy After Switching from Selective Serotonin Reuptake Inhibitors
|
Griffiths, RI
|
|
1998
|
1 |
1 |
p. 30-
1 p.
|
artikel
|
| 70 |
MHB1 Treatment Choice And the Incidence And Economic Intensity of Hospital Inpatient Use by Depressed Patients
|
Croghan, TW
|
|
1998
|
1 |
1 |
p. 30-
1 p.
|
artikel
|
| 71 |
MHC1 A Model of Primary Care Treatment of Major Depressive Disorder
|
Bell, EJ
|
|
1998
|
1 |
1 |
p. 47-
1 p.
|
artikel
|
| 72 |
MHC3 Factors Predicting Potentially Inappropriate Psychotropic Prescribing for the Elderly
|
Aparasu, RR
|
|
1998
|
1 |
1 |
p. 47-48
2 p.
|
artikel
|
| 73 |
MHC2 Medical And Economic Outcomes of Noncompliance with Dilantin in Adult Medicaid Epileptics
|
Singer, ME
|
|
1998
|
1 |
1 |
p. 47-
1 p.
|
artikel
|
| 74 |
MHC4 Testing The Reliability of Generic Quality-of-Life Measures in the Study of Multiple Sclerosis
|
Holmes, J
|
|
1998
|
1 |
1 |
p. 48-
1 p.
|
artikel
|
| 75 |
MHC5 The EuroQol in Parkinson's Disease Research: Rated Current Health vs. Population-Derived Health State Preferences
|
Chrischilles, EA
|
|
1998
|
1 |
1 |
p. 48-
1 p.
|
artikel
|
| 76 |
MM5 Comparing Computerized Options in Pharmacoeconomics: Spreadsheets, Decision Trees, And Educational Tools: An Open Workshop for Demonstrating Software
|
McGhan, WF
|
|
1998
|
1 |
1 |
p. 86-
1 p.
|
artikel
|
| 77 |
MM6 Decision Analysis: What is Its Utility for Pharmacoeconomic Analysis?
|
Caro, JJ
|
|
1998
|
1 |
1 |
p. 86-
1 p.
|
artikel
|
| 78 |
MM2 Designing Computer Models to Convey Cost-Effectiveness Analyses Results
|
Parente, ST
|
|
1998
|
1 |
1 |
p. 85-
1 p.
|
artikel
|
| 79 |
MM3 Development of Drug Use Performance Models as Measures of Patient Care
|
Holimon, TD
|
|
1998
|
1 |
1 |
p. 85-
1 p.
|
artikel
|
| 80 |
MM7 Issues in Developing Economic Models for Managed Care: The Case of Osteoporosis Prevention
|
Funk Orisini, P
|
|
1998
|
1 |
1 |
p. 86-87
2 p.
|
artikel
|
| 81 |
MM1 Monte Carlo Simulation in Health Care Models
|
Richter, A
|
|
1998
|
1 |
1 |
p. 84-85
2 p.
|
artikel
|
| 82 |
MM4 Reconciling Decision Models with the Real World: The Cost-Effectiveness of Erythropoietin for Esrd-Related Anemia
|
Kauf, T
|
|
1998
|
1 |
1 |
p. 85-86
2 p.
|
artikel
|
| 83 |
PCV2 An Analysis of the Economics of Hypertension
|
West, DS
|
|
1998
|
1 |
1 |
p. 49-
1 p.
|
artikel
|
| 84 |
PCV20 Convenience Implications of A Single Bolus Thrombolytic
|
Banks, JL
|
|
1998
|
1 |
1 |
p. 56-
1 p.
|
artikel
|
| 85 |
PCV21 Cost Consequences of Acute Myocardial Infarction in Diabetic Patients-The First Year
|
O'Brien, JA
|
|
1998
|
1 |
1 |
p. 56-
1 p.
|
artikel
|
| 86 |
PCV6 Development of A Decision-Analytic Model of Stroke Care in us And Europe
|
Chambers, M
|
|
1998
|
1 |
1 |
p. 50-51
2 p.
|
artikel
|
| 87 |
PCV7 Economic Evaluation of Torasimide in Congestive Heart Failure in Germany
|
Spannheimer, A
|
|
1998
|
1 |
1 |
p. 51-
1 p.
|
artikel
|
| 88 |
PCV4 Empirical Analysis of the Cost-Efficiency of HMG-COA Reductase Inhibitors
|
Foley, JL
|
|
1998
|
1 |
1 |
p. 50-
1 p.
|
artikel
|
| 89 |
PCV19 Evaluation of the Costs of Heart Failure in Belgium
|
Annemans, L
|
|
1998
|
1 |
1 |
p. 55-56
2 p.
|
artikel
|
| 90 |
PCV1 Factors Influencing the Decision to Treat Serum Lipid Disorders by Drug Therapy in the Primary Care Venue
|
Yuan, Y
|
|
1998
|
1 |
1 |
p. 49-
1 p.
|
artikel
|
| 91 |
PCV3 How Does Gender Affect Pharmacotherapy Treatment Decisions for Hypercholesterolemia/Hyperlipidemia?
|
Copeland, K
|
|
1998
|
1 |
1 |
p. 49-50
2 p.
|
artikel
|
| 92 |
PCV17 Lipid Therapy And Cardiovascular Disease: How Many Americans Should be Treated?
|
Yu, WM
|
|
1998
|
1 |
1 |
p. 55-
1 p.
|
artikel
|
| 93 |
PCV10 Medical And Economic Outcomes in Patients Treated with Diltiazem or Digoxin for Atrial Fibrillation: A Database Analysis
|
Windisch, PA
|
|
1998
|
1 |
1 |
p. 52-
1 p.
|
artikel
|
| 94 |
PCV14 Nonparametric Analysis of Cost-Effectiveness Ratios of Pravastatin in Primary Prevention of Cardiovascular Disease
|
Yuan, Y
|
|
1998
|
1 |
1 |
p. 54-
1 p.
|
artikel
|
| 95 |
PCV12 One-Year Clinical And Economic Outcomes of Primary Coronary Angioplasty Using A National Database
|
Akhras, KS
|
|
1998
|
1 |
1 |
p. 53-
1 p.
|
artikel
|
| 96 |
PCV5 Pharmaceutical Costs of Patient Non-Adherence to Lipid-Lowering Drug Therapy
|
Beck, P
|
|
1998
|
1 |
1 |
p. 50-
1 p.
|
artikel
|
| 97 |
PCV13 Prevalence And Cost of Hospitalizations Due to Angina in the United States Using A National Database
|
Akhras, KS
|
|
1998
|
1 |
1 |
p. 53-
1 p.
|
artikel
|
| 98 |
PCV8 Readiness to Comply And Outcomes of Antihypertensive Therapy
|
Garfield, FB
|
|
1998
|
1 |
1 |
p. 51-
1 p.
|
artikel
|
| 99 |
PCV16 Smoking Related Costs in the United States
|
Chua, WQ
|
|
1998
|
1 |
1 |
p. 54-55
2 p.
|
artikel
|
| 100 |
PCV9 Study of Hypertensive Prescribing Practices
|
Schulman, KA
|
|
1998
|
1 |
1 |
p. 52-
1 p.
|
artikel
|
| 101 |
PCV15 Study of Procedure Costs And Outcomes Associated with the Pharmacological Treatment of Arterial Disease And Intermittant Claudication in the Department of Claudication in the Department of Defense
|
Zachry, W
|
|
1998
|
1 |
1 |
p. 54-
1 p.
|
artikel
|
| 102 |
PCV18 The Impact of Acute Renal Failure on Cost in Elderly Patients with Congestive Heart Failure
|
Chen, Y-T
|
|
1998
|
1 |
1 |
p. 55-
1 p.
|
artikel
|
| 103 |
PCV11 The Impact of Unstable Angina on the Use of Medical Resources in Italy
|
Maggioni, AP
|
|
1998
|
1 |
1 |
p. 52-53
2 p.
|
artikel
|
| 104 |
PGD14 A Health Economic Analysis of Fluticasone Propionate, Budesonide, And Beclomethasone Dipropionate for the Treatment of Moderate to Severe Asthma
|
Trakas, K
|
|
1998
|
1 |
1 |
p. 62-
1 p.
|
artikel
|
| 105 |
PGD6 A Managed Care Cost Analysis of the Treatment of Psoriasis
|
Patterson, HK
|
|
1998
|
1 |
1 |
p. 59-
1 p.
|
artikel
|
| 106 |
PGD10 Bambuterol is A More Cost-Effective Treatment than Salmeterol in Asthma Patients with Nocturnal Symptoms
|
Crompton, GK
|
|
1998
|
1 |
1 |
p. 60-
1 p.
|
artikel
|
| 107 |
PGD8 Comparison of Prevalence Rates of Low Back Disorders Obtained from Two Large National Claims Databases
|
Dedhiya, SD
|
|
1998
|
1 |
1 |
p. 59-60
2 p.
|
artikel
|
| 108 |
PGD7 Consequences of High Hematocrit Maintenance among Hemodialysis Patients
|
Shih, Y
|
|
1998
|
1 |
1 |
p. 59-
1 p.
|
artikel
|
| 109 |
PGD4 Cost-Effectiveness Analysis of Screening of Type II Diabetes Mellitus in Nonpregnant Adults
|
Hui, RL
|
|
1998
|
1 |
1 |
p. 58-
1 p.
|
artikel
|
| 110 |
PGD12 Cost of Prescription Drugs And Cost of Treatment Failure for Sinusitis
|
Nadesan, B
|
|
1998
|
1 |
1 |
p. 61-
1 p.
|
artikel
|
| 111 |
PGD3 Cost-Utility Relation of the Treatment of Diabetic Foot Lesion with Hyperbaric Oxygene Therapy Versus Standard Therapy
|
Kilburg, A
|
|
1998
|
1 |
1 |
p. 57-58
2 p.
|
artikel
|
| 112 |
PGD13 Does the Duration of Pulmonary Rehabilitation Affect the Magnitude of Patient Response?
|
Barr, JT
|
|
1998
|
1 |
1 |
p. 61-62
2 p.
|
artikel
|
| 113 |
PGD9 Outcomes And Cost-Benefit of Inhaled Corticosteroid Therapy Introduction in Medicaid-Enrolled Asthmatic Children
|
Balkrishnan, R
|
|
1998
|
1 |
1 |
p. 60-
1 p.
|
artikel
|
| 114 |
PGD5 Predicting Hospitalization of Patients with Diabetes Mellitus: An Application of the Bayesian Discriminant Analysis
|
Bhattacharyya, S
|
|
1998
|
1 |
1 |
p. 58-59
2 p.
|
artikel
|
| 115 |
PGD2 The Economic Implications of Decreased Patient Adherence to Co-Prescribed Diclofenac And Misoprostol (CORX-D&M) Relative to A Single-Tablet Formulation of Diclofenac/Misoprostol (STF-D/M)
|
Goldstein, JL
|
|
1998
|
1 |
1 |
p. 57-
1 p.
|
artikel
|
| 116 |
PGD1 The Effects of Community-Based Pharmaceutical Care Services on Asthma-Related Quality of Life
|
Boyd, BJ
|
|
1998
|
1 |
1 |
p. 57-
1 p.
|
artikel
|
| 117 |
PGD11 Validity And Reliability of An American Translation of the St. George's Respiratory Questionnaire
|
Barr, JT
|
|
1998
|
1 |
1 |
p. 61-
1 p.
|
artikel
|
| 118 |
PGD15 Veterans' Satisfaction with H2-Receptor Antagonist (H2RA) Drug Conversion
|
|
|
1998
|
1 |
1 |
p. 62-
1 p.
|
artikel
|
| 119 |
PHB8 Cost-Effectiveness of Hormone Therapy Versus Calcium Therapy: An Osteoporosis Markov Model
|
Keys, PJ
|
|
1998
|
1 |
1 |
p. 65-66
2 p.
|
artikel
|
| 120 |
PHB11 Determining Minimally Important Changes (MIC) in Rheumatoid Arthritis (RA) Functional Status
|
Bagchi, I
|
|
1998
|
1 |
1 |
p. 67-
1 p.
|
artikel
|
| 121 |
PHB1 Efficient Strategies for Osteoporosis Testing
|
Abbott, TA
|
|
1998
|
1 |
1 |
p. 62-63
2 p.
|
artikel
|
| 122 |
PHB6 Health Care Use in Women Age 45 And Older
|
Hoerger, TJ
|
|
1998
|
1 |
1 |
p. 64-65
2 p.
|
artikel
|
| 123 |
PHB3 Psychometric Evaluation of SF-12 in Osteoarthritis Clinical Trials
|
Gandhi, SK
|
|
1998
|
1 |
1 |
p. 63-64
2 p.
|
artikel
|
| 124 |
PHB10 Quality of Life And Pharmacoeconomic Aspects of Hormone Replacement Therapy in Post-Menopausal Women—A Canadian Randomized Trial
|
Haider, S
|
|
1998
|
1 |
1 |
p. 66-
1 p.
|
artikel
|
| 125 |
PHB2 SF-12 Osteoarthritis-Specific Health Index: Development And Validation
|
Gandhi, SK
|
|
1998
|
1 |
1 |
p. 63-
1 p.
|
artikel
|
| 126 |
PHB7 The Direct Medical Cost of Osteporotic Fractures
|
Martin, BC
|
|
1998
|
1 |
1 |
p. 65-
1 p.
|
artikel
|
| 127 |
PHB5 The Responsiveness of Disease-Specific And Generic Health Measures to Changes in the Severity of Osteoarthritis
|
Zhao, S
|
|
1998
|
1 |
1 |
p. 64-
1 p.
|
artikel
|
| 128 |
PHB4 The Responsiveness of Disease-Specific And Generic Health Measures to Changes in the Severity of Rheumatoid Arthritis And to Treatment
|
Kosinski, M
|
|
1998
|
1 |
1 |
p. 64-
1 p.
|
artikel
|
| 129 |
PHB9 Use of Centralized Pharmacy Records in A Managed Care Organization to Determine Effect of Educational Material on Hormone Replacement Therapy Patient Compliance
|
Chen, Y
|
|
1998
|
1 |
1 |
p. 66-
1 p.
|
artikel
|
| 130 |
PIC11 A Health Economic Evaluation of Paclitaxel And Carboplatin Versus Vinorelbine And Cisplatin Combination Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
|
Sinha, N
|
|
1998
|
1 |
1 |
p. 71-
1 p.
|
artikel
|
| 131 |
PIC8 Clinical And Economic Benefits of An Infectious Disease Approval Program
|
Kinky, DE
|
|
1998
|
1 |
1 |
p. 70-
1 p.
|
artikel
|
| 132 |
PIC3 Colorectal Cancer Screening: Cost-Effectiveness Analysis from An Italian Viewpoint
|
Bona, M
|
|
1998
|
1 |
1 |
p. 68-
1 p.
|
artikel
|
| 133 |
PIC5 Cost-Effectiveness Analysis of Piperacillin-Tazobactam Versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections
|
Dominguez-Gil, A
|
|
1998
|
1 |
1 |
p. 68-69
2 p.
|
artikel
|
| 134 |
PIC4 Cost-Effectiveness of Piperacillin-Tazobactam Versus Ceftazidime in Patients with Febrile Neutropenia
|
Dominguez-Gil, A
|
|
1998
|
1 |
1 |
p. 68-
1 p.
|
artikel
|
| 135 |
PIC7 Epoetin Alfa Administered to Academic Health Center Dialysis Patients: Comparison to HCFA Billing Records
|
Chen, C
|
|
1998
|
1 |
1 |
p. 69-
1 p.
|
artikel
|
| 136 |
PIC1 Markov Chain Estimation of Life Expectancy of HIV-Infected Patients: Comparison of Two Treatment Alternatives
|
Bhattacharyya, SK
|
|
1998
|
1 |
1 |
p. 67-
1 p.
|
artikel
|
| 137 |
PIC2 Socioeconomic Relevance of Inpatient Treatment of Intra-Abdominal Infections with Tazobactam/Piperacillin 0.5 g/4.0 g in Comparison with Imipenem/Cilastatin
|
Bruchhausen, Y
|
|
1998
|
1 |
1 |
p. 67-68
2 p.
|
artikel
|
| 138 |
PIC9 The Economic Impact of A Drug Information Service
|
Kinky, DE
|
|
1998
|
1 |
1 |
p. 70-
1 p.
|
artikel
|
| 139 |
PIC10 The Influence of Case Mix Bias On Costs of Hospitalisation for Lower Respiratory Tract Infection
|
Peter, Davey
|
|
1998
|
1 |
1 |
p. 70-71
2 p.
|
artikel
|
| 140 |
PIC6 Using A Pneumonia-Specific Severity of Illness Model in Assessing Variation in Hospital Length of Stay for Community-Acquired Pneumonia Patients
|
Tan, H
|
|
1998
|
1 |
1 |
p. 69-
1 p.
|
artikel
|
| 141 |
PMD15 An Unbiased Method of Pharmaceutical Cost Analysis
|
Nichol, G
|
|
1998
|
1 |
1 |
p. 77-
1 p.
|
artikel
|
| 142 |
PMD13 Application of Pharmacoeconomics And Outcomes Research in Formulary Decision-Making
|
Sarpong, DF
|
|
1998
|
1 |
1 |
p. 76-
1 p.
|
artikel
|
| 143 |
PMD6 Chronic Care Costs of New Medicare HMO Enrollees: Implications for Disease Management
|
Grannemann, TW
|
|
1998
|
1 |
1 |
p. 73-
1 p.
|
artikel
|
| 144 |
PMD9 Evaluation of A Pathway for Providing Pharmaceutical Care
|
Burgess, S
|
|
1998
|
1 |
1 |
p. 74-
1 p.
|
artikel
|
| 145 |
PMD16 Implication of Preventing Disease on Life Years Gained (LYG)
|
Caro, JJ
|
|
1998
|
1 |
1 |
p. 77-
1 p.
|
artikel
|
| 146 |
PMD1 Information Technology in A Large Multi-Site Outcomes Study
|
Morlock, R
|
|
1998
|
1 |
1 |
p. 71-
1 p.
|
artikel
|
| 147 |
PMD4 Outcomes Research Interests of A Community Pharmacist Research Network
|
Wade, WE
|
|
1998
|
1 |
1 |
p. 72-73
2 p.
|
artikel
|
| 148 |
PMD8 Prenatal Care And Birth Weight in the United States
|
Feng, W
|
|
1998
|
1 |
1 |
p. 74-
1 p.
|
artikel
|
| 149 |
PMD5 Prescription Medication Use in Older Americans
|
Mehta, SS
|
|
1998
|
1 |
1 |
p. 73-
1 p.
|
artikel
|
| 150 |
PMD17 Surveillance of A New Drug in the United Kingdom
|
Hartz, SC
|
|
1998
|
1 |
1 |
p. 77-78
2 p.
|
artikel
|
| 151 |
PMD10 The Development of A Patient Outcomes Software for Urologists: Capsure POS™
|
Flanders, S
|
|
1998
|
1 |
1 |
p. 75-
1 p.
|
artikel
|
| 152 |
PMD2 The Effect of the Louisiana Medicaid Lock-in on Prescription Drug Utilization And Expenditures
|
Blake, SG
|
|
1998
|
1 |
1 |
p. 72-
1 p.
|
artikel
|
| 153 |
PMD12 The Paradox of League Tables
|
Caro, JJ
|
|
1998
|
1 |
1 |
p. 75-76
2 p.
|
artikel
|
| 154 |
PMD7 The Value of Medicines: Is There Enough Economic Evidence?
|
Constenla, D
|
|
1998
|
1 |
1 |
p. 73-74
2 p.
|
artikel
|
| 155 |
PMD11 Use of Administrative Databases in Saskatchewan, Canada, for Pharmacoeconomic and Outcomes Research
|
Downey, W
|
|
1998
|
1 |
1 |
p. 75-
1 p.
|
artikel
|
| 156 |
PMD3 Use of Administrative Data to Create Disease-Specific Datasets for Use in Health Economic Studies
|
Beck, P
|
|
1998
|
1 |
1 |
p. 72-
1 p.
|
artikel
|
| 157 |
PMD14 Vox Populi: Stated Preferences for Pharmaceutical Innovations
|
Bingham, MF
|
|
1998
|
1 |
1 |
p. 76-
1 p.
|
artikel
|
| 158 |
PMH7 A General Model of the Effects of Alternative Sedative-Hypnotic Agents on the Costs of Motor Vehicle Accidents
|
Menzin, J
|
|
1998
|
1 |
1 |
p. 80-
1 p.
|
artikel
|
| 159 |
PMH16 A Health Policy Analysis of Pharmacotherapy for Major Depressive Disorder in Europe And the Americas
|
Arikian, SR
|
|
1998
|
1 |
1 |
p. 84-
1 p.
|
artikel
|
| 160 |
PMH2 Assessment of Health-Related Quality of Life During Treatment of Opiate Dependence Using the Short Form-36
|
Raisch, DW
|
|
1998
|
1 |
1 |
p. 78-
1 p.
|
artikel
|
| 161 |
PMH13 Developing A Task-Based Instrument to Measure Migraine-Related Productivity
|
Lee, TA
|
|
1998
|
1 |
1 |
p. 82-83
2 p.
|
artikel
|
| 162 |
PMH15 Development of A Self-Administered Outcome Measure for Use in An Outpatient Population of Individuals with Schizophrenia
|
Barr, JT
|
|
1998
|
1 |
1 |
p. 83-
1 p.
|
artikel
|
| 163 |
PMH8 Duration of Continuous Therapy Between Atypical And Typical Antipsychotics
|
Li, Z
|
|
1998
|
1 |
1 |
p. 80-81
2 p.
|
artikel
|
| 164 |
PMH6 Economic Outcomes of Antidepressant Use in A Managed Care Organization
|
White, TJ
|
|
1998
|
1 |
1 |
p. 80-
1 p.
|
artikel
|
| 165 |
PMH3 Evaluation of Humanistic Outcomes for Patients on Selective Serotonin Reuptake Inhibitors
|
Sansgiry, SS
|
|
1998
|
1 |
1 |
p. 78-79
2 p.
|
artikel
|
| 166 |
PMH9 Month-to-Month Adherence with Antipsychotic Pharmacotherapy: A Comparison Between Atypical And Typical Antipsychotics
|
Li, Z
|
|
1998
|
1 |
1 |
p. 81-
1 p.
|
artikel
|
| 167 |
PMH4 Quality of Life And Adverse Reactions in Depressed Patients Receiving Antidepressant Drugs
|
Taylor, AT
|
|
1998
|
1 |
1 |
p. 79-
1 p.
|
artikel
|
| 168 |
PMH14 Schizophrenia Management: Does Managed Care Influence Length of Stay in U.S. Hospitals?
|
O'Brien, JA
|
|
1998
|
1 |
1 |
p. 83-
1 p.
|
artikel
|
| 169 |
PMH10 Selective Serotonin Reuptake Inhibitor Utilization Patterns: Consistency Across Research Designs
|
Hutchins, DS
|
|
1998
|
1 |
1 |
p. 81-
1 p.
|
artikel
|
| 170 |
PMH12 Texas Medication Algorithm Project: Feasibility Study of Implementing Medication Algorithms in the Public Mental Health Sector
|
Crismon, ML
|
|
1998
|
1 |
1 |
p. 82-
1 p.
|
artikel
|
| 171 |
PMH5 The Cost of Treating Schizophrenia in the California Medicaid (MEDI-CAL) Program
|
McCombs, JS
|
|
1998
|
1 |
1 |
p. 79-80
2 p.
|
artikel
|
| 172 |
PMH1 The Economic Burden of Schizophrenia: Acute General Hospital Costs
|
O'Brien, JA
|
|
1998
|
1 |
1 |
p. 78-
1 p.
|
artikel
|
| 173 |
PMH17 Utilization Patterns of Antidepressant Medications in A Patient Population Served by A Primary Care Medical Group
|
Venturini, F
|
|
1998
|
1 |
1 |
p. 84-
1 p.
|
artikel
|
| 174 |
PMH11 Utlization Review of SSRI Therapy at A Mental Health Managed Care Organization
|
Conner, TM
|
|
1998
|
1 |
1 |
p. 82-
1 p.
|
artikel
|
| 175 |
UT2 Practical Applications of the Health Utilities Index
|
Torrance, GW
|
|
1998
|
1 |
1 |
p. 93-
1 p.
|
artikel
|
| 176 |
UT3 The EuroQoL EQ-5D: An Outcome Measure for Use in Clinical And Economic Evaluation
|
Kind, P
|
|
1998
|
1 |
1 |
p. 93-94
2 p.
|
artikel
|
| 177 |
UT1 Trade-Off Preferences for Pharmaceutical Development, Marketing, And Outcomes Evaluation
|
Johnson, FR
|
|
1998
|
1 |
1 |
p. 93-
1 p.
|
artikel
|
Tijdschrift beschrijving